UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | January 4, 2012 |
Illumina, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 000-30361 | 33-0804655 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
5200 Illumina Way, San Diego, California | 92122 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | (858) 202-4500 |
9885 Towne Centre Drive, San Diego, CA 92121
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 4, 2012, Illumina, Inc. (the "Company") announced the appointment of Marc A. Stapley as Senior Vice President and Chief Financial Officer of the Company. Mr. Stapley will assume the position of Chief Financial Officer from Christian O. Henry, who has been the Company’s Chief Financial Officer since 2005. Mr. Henry will continue in his role with the Company as Senior Vice President and General Manager, Genetic Analysis (formerly Life Sciences).
Mr. Stapley, age 42, most recently served as Senior Vice President, Finance at Pfizer, Inc. where he was responsible for global financial processes and systems and oversaw approximately 1,200 colleagues and outsourced contractors in North America, Europe, and Asia. Prior to joining Pfizer in 2009, Mr. Stapley spent eight years at Alcatel-Lucent USA, Inc. where he last served as Chief Financial Officer, Americas and prior to that served as Controller, Wireless Business Group; Finance Vice President, Network Solutions Group and Supply Chain Networks; and Vice President and Director, Financial Planning and Analysis.
In accordance with the terms of an employment offer letter between the Company and Mr. Stapley, Mr. Stapley will be employed at will by the Company. Mr. Stapley’s start date with the Company is expected to be January 20, 2012. The employment offer letter provides for the following:
• annual base salary of $435,000;
• eligibility to participate in the Company's executive variable compensation plan, which is an "at-risk" cash bonus compensation program, with a target award amount of 55% of base salary, subject to the achievement of individual and corporate performance objectives;
• a sign-on cash award of $350,000 (one-half of which is payable within 30 days of his start date and one-half of which is payable following the six month anniversary of his start date) that must be repaid in full if Mr. Stapley voluntarily terminates employment or is dismissed due to gross negligence or misconduct within 12 months of his start date;
• a new hire grant of 24,500 restricted stock units to be awarded on his start date, vesting over four years with 25 percent of the RSUs vesting on each of the first four anniversaries of the grant date;
• a new hire grant of 136,500 stock options to be granted on his start date, having an exercise price equal to the closing fair market value of the Company’s common stock on the grant date, a ten-year term, and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter; and
• eligibility to participate in the Company's compensation and benefit plans and programs as may generally be made available to other executives of the Company at his level.
A copy of the press release announcing the appointment of Mr. Stapley is attached as Exhibit 99.1 to this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Illumina, Inc. | ||||
January 4, 2012 | By: |
Christian G. Cabou
|
||
|
||||
Name: Christian G. Cabou | ||||
Title: Senior Vice President & General Counsel |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99
|
Press Release, dated January 4, 2012 |
Illumina Appoints Marc Stapley as Senior Vice President and Chief Financial Officer
Stapley Brings Multi-National Experience in High-Growth and Mature Industries
SAN DIEGO, January 4, 2012 (BUSINESS WIRE)Illumina, Inc. (NASDAQ: ILMN) today announced it has named Marc Stapley, former Senior Vice President, Finance, at Pfizer and Americas Chief Financial Officer at Alcatel-Lucent, to the position of Senior Vice President and Chief Financial Officer.
Stapley will report to President and Chief Executive Officer Jay Flatley and will oversee Illuminas finance, accounting, facilities and investor relations functions. He will also become part of Illuminas executive management team, which is responsible for directing all aspects of company strategy, planning and operations.
Marc is an ideal fit for the fast-paced culture of Illumina, said Jay Flatley. He is a dynamic finance leader whose experience spans leading high-tech and pharmaceutical companies where he has helped transform the finance functions, directed ERP implementations, effectively identified cost reduction initiatives and led acquisition integration efforts.
I am honored to take the role of Illuminas CFO and join such a world-class team, said Stapley. The Company is in a critical growth and development stage, and I look forward to supporting the continued innovation and performance that the company has delivered over many years.
Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, leading integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the companys largest technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems. Stapley began his career as an Auditor at Coopers & Lybrand. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.
Stapley is expected to join Illumina on January 20, 2012. At that time he will assume the CFO responsibilities currently held by Christian Henry. Henry, who for the past two years has been serving in both the CFO role and as GM of the Companys Genetic Analysis business (formerly Life Sciences), will now be able to fully dedicate his time to leading our Genetic Analysis business.
I would like to thank Christian for the outstanding contributions he has made to Illumina in the CFO role, said Jay Flatley. Since 2005, Christian has developed a world-class finance organization and led multiple corporate financings, acquisitions and facility relocations. I look forward to the impact he can make by solely focusing on driving our Genetic Analysis Business.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life
science tools and integrated systems for the analysis of genetic variation and function. We provide
innovative sequencing and array-based solutions for genotyping, copy number variation analysis,
methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in consumer genomics and
diagnostics. Our technology and products accelerate genetic analysis research and its application,
paving the way for molecular medicine and ultimately transforming healthcare.
# # #
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Laura Trotter
Public Relations
858-882-6822
PR@illumina.com